PET with 18F-Fluorodeoxyglucose/Computed Tomography in the Management of Pediatric Sarcoma

Douglas J. Harrison; Marguerite T. Parisi; Hedieh Khalatbari; Barry L. Shulkin

doi:10.1016/j.cpet.2020.03.008

PET with ¹⁸F-Fluorodeoxyglucose/Computed Tomography in the Management of Pediatric Sarcoma

Douglas J. Harrison
, Marguerite T. Parisi
, Hedieh Khalatbari
, Barry L. Shulkin

University of Texas MD Anderson Cancer Center
Seattle Children's

Research output: Contribution to journal › Review article › peer-review

15 Scopus citations

Abstract

The role for PET with fludeoxyglucose F 18 (¹⁸F-FDG PET)/computed tomography (CT) in the management of pediatric sarcomas continues to be controversial. The literature supports a role for PET/CT in the staging and surveillance of certain specific pediatric sarcoma subtypes; however, the data are less clear regarding whether PET/CT can be used as a biomarker for prognostication. Despite the interest in using this imaging modality in the management of pediatric sarcomas, most studies are limited by retrospective design and small sample size. Additional data are necessary to fully understand how best to use ¹⁸F-FDG PET/CT in pediatric sarcoma management.

Original language	English
Pages (from-to)	333-347
Number of pages	15
Journal	PET Clinics
Volume	15
Issue number	3
DOIs	https://doi.org/10.1016/j.cpet.2020.03.008
State	Published - Jul 2020
Externally published	Yes

Keywords

F-FDG PET/CT
Ewing sarcoma
Non-rhabdomyosarcoma soft tissue sarcoma
Osteosarcoma
Rhabdomyosarcoma

Access to Document

10.1016/j.cpet.2020.03.008

Cite this

@article{8a98237b110e41629aa7ae1d6d7347f2,

title = "PET with 18F-Fluorodeoxyglucose/Computed Tomography in the Management of Pediatric Sarcoma",

abstract = "The role for PET with fludeoxyglucose F 18 (18F-FDG PET)/computed tomography (CT) in the management of pediatric sarcomas continues to be controversial. The literature supports a role for PET/CT in the staging and surveillance of certain specific pediatric sarcoma subtypes; however, the data are less clear regarding whether PET/CT can be used as a biomarker for prognostication. Despite the interest in using this imaging modality in the management of pediatric sarcomas, most studies are limited by retrospective design and small sample size. Additional data are necessary to fully understand how best to use 18F-FDG PET/CT in pediatric sarcoma management.",

keywords = "F-FDG PET/CT, Ewing sarcoma, Non-rhabdomyosarcoma soft tissue sarcoma, Osteosarcoma, Rhabdomyosarcoma",

author = "Harrison, \{Douglas J.\} and Parisi, \{Marguerite T.\} and Hedieh Khalatbari and Shulkin, \{Barry L.\}",

note = "Publisher Copyright: {\textcopyright} 2020 Elsevier Inc.",

year = "2020",

month = jul,

doi = "10.1016/j.cpet.2020.03.008",

language = "English",

volume = "15",

pages = "333--347",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders",

number = "3",

}

TY - JOUR

T1 - PET with 18F-Fluorodeoxyglucose/Computed Tomography in the Management of Pediatric Sarcoma

AU - Harrison, Douglas J.

AU - Parisi, Marguerite T.

AU - Khalatbari, Hedieh

AU - Shulkin, Barry L.

PY - 2020/7

Y1 - 2020/7

N2 - The role for PET with fludeoxyglucose F 18 (18F-FDG PET)/computed tomography (CT) in the management of pediatric sarcomas continues to be controversial. The literature supports a role for PET/CT in the staging and surveillance of certain specific pediatric sarcoma subtypes; however, the data are less clear regarding whether PET/CT can be used as a biomarker for prognostication. Despite the interest in using this imaging modality in the management of pediatric sarcomas, most studies are limited by retrospective design and small sample size. Additional data are necessary to fully understand how best to use 18F-FDG PET/CT in pediatric sarcoma management.

AB - The role for PET with fludeoxyglucose F 18 (18F-FDG PET)/computed tomography (CT) in the management of pediatric sarcomas continues to be controversial. The literature supports a role for PET/CT in the staging and surveillance of certain specific pediatric sarcoma subtypes; however, the data are less clear regarding whether PET/CT can be used as a biomarker for prognostication. Despite the interest in using this imaging modality in the management of pediatric sarcomas, most studies are limited by retrospective design and small sample size. Additional data are necessary to fully understand how best to use 18F-FDG PET/CT in pediatric sarcoma management.

KW - F-FDG PET/CT

KW - Ewing sarcoma

KW - Non-rhabdomyosarcoma soft tissue sarcoma

KW - Osteosarcoma

KW - Rhabdomyosarcoma

UR - https://www.scopus.com/pages/publications/85085640969

U2 - 10.1016/j.cpet.2020.03.008

DO - 10.1016/j.cpet.2020.03.008

M3 - Review article

C2 - 32498989

AN - SCOPUS:85085640969

SN - 1556-8598

VL - 15

SP - 333

EP - 347

JO - PET Clinics

JF - PET Clinics

IS - 3

ER -

PET with ¹⁸F-Fluorodeoxyglucose/Computed Tomography in the Management of Pediatric Sarcoma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this